TXNIP and chronic myelogenous leukemia, BCR-ABL1 positive: Since the key role of TXNIP in increasing imatinib sensitivity and counteracting drug resistance in CML cells, it is reasonable to determine the synergistic inhibitory effect of imatinib with drugs targeting TXNIP.